



JAMA Oncol. 2020 Feb; 6(2): e193332.

PMCID: PMC6764147

Published online 2019 Sep 26. doi: 10.1001/jamaoncol.2019.3332:

PMID: [31556911](#)

10.1001/jamaoncol.2019.3332

Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial

[Amylou C. Dueck](#), PhD,¹ [Howard I. Scher](#), MD,² [Antonia V. Bennett](#), PhD,³ [Gina L. Mazza](#), PhD,¹ [Gita Thanarajasingam](#), MD,⁴ [Gisela Schwab](#), MD,⁵ [Aaron L. Weitzman](#), MD,⁶ [Lauren J. Rogak](#), MA,⁷ and [Ethan Basch](#), MD, MSc^{✉3}

¹Department of Health Sciences Research, Mayo Clinic, Scottsdale, Arizona

²Department of Medicine, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, New York

³Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

⁴Division of Hematology, Mayo Clinic, Rochester, Minnesota

⁵Exelixis Inc, South San Francisco, California

⁶Independent Consultant, San Francisco, California

⁷Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York

[✉]Corresponding author.

Article Information

Accepted for Publication: June 15, 2019.

Corresponding Author: Ethan Basch, MD, MSc, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 170 Manning Dr, Chapel Hill, NC 27516 (ebasch@med.unc.edu).

Published Online: September 26, 2019. doi:10.1001/jamaoncol.2019.3332

Author Contributions: Dr Dueck had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Dueck, Scher, Bennett, Schwab, Weitzman, Basch.

Acquisition, analysis, or interpretation of data: Dueck, Mazza, Thanarajasingam, Schwab, Rogak, Basch.

Drafting of the manuscript: Dueck, Thanarajasingam, Rogak, Basch.

Critical revision of the manuscript for important intellectual content: Dueck, Scher, Bennett, Mazza, Thanarajasingam, Schwab, Weitzman, Basch.

Statistical analysis: Dueck, Mazza, Thanarajasingam.

Obtained funding: Scher.

Administrative, technical, or material support: Scher, Schwab, Rogak.

Supervision: Scher, Schwab, Basch.

Conflict of Interest Disclosures: Dr Dueck reported receiving grants from the National Cancer Institute during the conduct of the study. Dr Scher reported receiving personal fees and nonfinancial support from Asterias Biotherapeutics, Ambry Genetics Corp, Konica Minolta Inc, and WCG Oncology; nonfinancial support from Amgen, ESSA Pharma Inc, Janssen R & D, Janssen Biotech Inc, Menarini Silicon, Sanofi, and Clovis Oncology; and grants from Epic Sciences, Illumina Inc, Innocrin Pharma, Janssen, Menarini Silicon, and Thermo Fisher outside the submitted work. Dr Mazza reported receiving grants from the National Cancer Institute during the conduct of the study. Dr Thanarajasingam reported receiving grants from the National Institutes of Health during the conduct of the study. Dr Schwab reported being an employee and shareholder of Exelixis Inc, the company that sponsored the clinical trial providing data for this publication. Dr Basch reported receiving grants from the National Cancer Institute and the Patient-Centered Outcomes Research Institute; editorial support from *JAMA*; research consultant fees from Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center; primary employment from University of North Carolina; and personal fees from Sivan, CareVive, and Self Care Catalyst outside the submitted work. No other disclosures were reported.

Funding/Support: Funding for this analysis was provided through the Cancer Moonshot initiative of the US National Cancer Institute (grant U01 CA233046).

Role of the Funder/Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Information: Data were provided by Exelixis Inc for this trial, but Exelixis Inc did not provide any funds and did not participate in the decision to submit this manuscript, analysis, or approval of the submission.

Received 2019 Apr 1; Accepted 2019 Jun 15.

[Copyright](#) 2019 American Medical Association. All Rights Reserved.

Key Points

Question

Is implementation of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) feasible in a phase 3 cancer trial, and how well can PRO-CTCAE be used to detect between-group differences in symptomatic adverse events relative to the Common Terminology Criteria for Adverse Events?

Findings

In this prespecified correlative analysis of the randomized COMET-2 trial of 119 patients with prostate cancer in which patients completed the PRO-CTCAE at baseline and every 3 weeks during treatment, 534 of 587 (91.0%) expected PRO-CTCAE self-reports were completed. The

rates of 7 symptomatic adverse events were statistically significantly different between groups by PRO-CTCAE, while none were statistically significantly different by the Common Terminology Criteria for Adverse Events.

Meaning

PRO-CTCAE data collection was feasible and improved the accuracy of symptomatic adverse event detection in this phase 3 cancer trial.

Abstract

Importance

Standard adverse event (AE) reporting in oncology clinical trials has historically relied on clinician grading, which prior research has shown can lead to underestimation of rates of symptomatic AEs. Industry sponsors are beginning to implement in trials the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), which was developed to allow patients to self-report symptomatic AEs and improve the quality of symptomatic AE detection.

Objectives

To evaluate the feasibility of implementing PRO-CTCAE in a prespecified correlative analysis of the phase 3 COMET-2 trial and enumerate statistically significant between-group differences in symptomatic AEs using PRO-CTCAE and the CTCAE.

Design, Setting, and Participants

This correlative study of 119 men in the randomized, double-blind, placebo-controlled phase 3 COMET-2 trial with metastatic castration-resistant prostate cancer who had undergone at least 2 prior lines of systemic treatment was conducted from March 2012 to July 2014. Participants completed PRO-CTCAE items using an automated telephone system from home prior to treatment and every 3 weeks during treatment. Statistical analysis was performed from May 2018 to June 2019.

Main Outcomes and Measures

The proportion of patients who completed expected PRO-CTCAE self-reports was computed as a measure of feasibility.

Results

Among the 119 men in the study (median age, 65 years [range, 44-80 years]), 534 of 587 (91.0%) expected PRO-CTCAE self-reports were completed, with consistently high rates of completion throughout participation. Rates of self-report adherence were similar between groups (cabozantinib s-maleate, 286 of 317 [90.2%]; and mitoxantrone hydrochloride-pred-

nisone, 248 of 270 [91.9%]). Of 12 measured, patient-reported PRO-CTCAE symptomatic AEs, 4 reached statistical significance when comparing the proportion of patients with at least 1 post-baseline score greater than 0 between groups (differences ranged from 20.1% to 34.1% with higher proportions in the cabozantinib group; all $P < .05$), and use of a method for accounting for preexisting symptoms at baseline yielded 7 AEs with statistically significant differences between groups (differences ranged from 20.5% to 41.2% with higher proportions in the cabozantinib group; all $P < .05$). In the same analysis using investigator-reported CTCAE data, no statistically significant differences were found between groups for any symptomatic AEs.

Conclusions and Relevance

PRO-CTCAE data collection was feasible and improved the accuracy of symptomatic AE detection in a phase 3 cancer trial. This analysis adds to mounting evidence of the feasibility and value of patient-reported AEs in oncology, which should be considered for inclusion in cancer trials that incorporate AE evaluation.

Trial Registration

ClinicalTrials.gov identifier: [NCT01522443](https://clinicaltrials.gov/ct2/show/study/NCT01522443)

This prespecified correlative analysis of a randomized clinical trial evaluates the feasibility of implementing the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events in the phase 3 COMET-2 trial.

Introduction

Prior research reveals that investigators miss up to half of study participants' symptomatic adverse events (AEs) in drug development trials (eg, nausea or sensory neuropathy), leading to potential underestimations of harms.¹ To improve the quality of symptomatic AE detection in trials, the National Cancer Institute developed a patient-reported version of its standard AE lexicon, the Common Terminology Criteria for Adverse Events (CTCAE), which is called the Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE). Industry sponsors are now beginning to implement PRO-CTCAE across the continuum of trials including early-phase, phase 3, and postmarketing studies. The US Food and Drug Administration has encouraged adoption of this tool in oncology trials.²

The PRO-CTCAE is an item library that includes individual patient questions representing 78 unique symptomatic AEs.³ Items are phrased in patient-friendly lay language (eg, "mouth or throat sores" for oral mucositis) and have undergone rigorous psychometric development and validation.^{4,5} The PRO-CTCAE includes up to 3 discrete questions for each AE, separately representing the frequency, severity, and/or interference with daily activities of the event. Items may be downloaded for use in trials from the National Cancer Institute at <http://healthcaredelivery.cancer.gov/pro-ctcae>.

Investigators may select PRO-CTCAE items that are pertinent to a given trial context based on known and anticipated properties of study drugs.⁶ These items can be administered to patients via paper or electronic forms at baseline, regularly during treatment, and after treatment (eg, weekly during active treatment and every 3 months during follow-up).

Methods

The PRO-CTCAE was implemented in a randomized, double-blind, placebo-controlled, phase 3 registration-track trial called COMET-2 comparing 60 mg of cabozantinib s-maleate once daily vs 12 mg/m² of mitoxantrone hydrochloride every 3 weeks plus 5 mg of oral prednisone twice daily in men with metastatic castration-resistant prostate cancer who had undergone at least 2 prior lines of systemic treatment (clinical results reported elsewhere).⁷ This prespecified correlative analysis of the COMET-2 trial was conducted from March 2012 to July 2014. All patients provided written informed consent. The study was approved by the institutional review board or ethics committee at each center⁷ and conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki.⁸ An independent data monitoring committee monitored patient safety. The trial was discontinued early owing to negative overall survival results of a companion phase 3 trial (COMET-1), which compared cabozantinib vs placebo in this population.⁹

All patients enrolling in COMET-2 were trained to self-report PRO-CTCAE items with a 7-day recall period using an automated telephone system (ie, interactive voice response system). This system would call the patient every 3 weeks to self-report, with up to 2 reminder calls if a patient missed the initial call(s). The PRO-CTCAE items included 12 symptomatic AEs: insomnia, constipation, pain, fatigue, nausea, vomiting, diarrhea, rash, decreased appetite, numbness or tingling, mouth sores, and shortness of breath. Items were administered only during active treatment.

Statistical analysis was performed from May 2018 to June 2019. To assess feasibility of the PRO-CTCAE approach to AE reporting, the proportion of patients who completed expected PRO-CTCAE self-reports was computed. Scores on the PRO-CTCAE's 0 to 4 scale were compared between groups using the common standard approach that is typically applied to longitudinal CTCAE data in cancer trials. The maximum postbaseline score for each AE was tabulated per patient. Then, the proportion of participants by group with a maximum postbaseline score greater than 0, and subsequently for a score of 3 or more, was computed and compared between groups using Fisher exact tests. This analysis was repeated using a previously described baseline adjustment method,⁶ computed per PRO-CTCAE item per patient as the maximum postbaseline score if that maximum score was worse than the patient's baseline score or a score of 0 if that maximum score was the same or better than the patient's baseline score. The method for comparing correlated receiver operating characteristic curves of DeLong et al¹⁰ was used to assess whether maximum score with or without baseline adjustment (each dichotomized as a score of 0 vs ≥ 1) better differentiated between study groups by individual AE and overall.

Results

At the time of trial discontinuation, COMET-2 had enrolled 119 participants, of which 114 completed a baseline PRO-CTCAE questionnaire, 112 completed at least 1 follow-up PRO-CTCAE questionnaire, and 107 completed a baseline PRO-CTCAE questionnaire and at least 1 follow-up PRO-CTCAE questionnaire. PRO-CTCAE analysis included these 107 patients, all of whom received study treatment. Median age was 65 years (range, 44-80 years), 100 of 119 participants (84.0%) were white, 105 of 119 (88.2%) had a baseline Eastern Cooperative Oncology Group performance status of 0 to 1, and 72 of 119 (60.5%) had 5 or more prior lines of systemic treatment for castration-resistant metastatic prostate cancer.

There were 587 time points at which a PRO-CTCAE self-report was expected, of which 534 reports (91.0%) were completed, with consistently high rates of completion throughout participation. Rates were similar between groups (cabozantinib, 286 of 317 [90.2%]; mitoxantrone-prednisone, 248 of 270 [91.9%]) (eTable 1 in the [Supplement](#)).

Baseline PRO-CTCAE scores were balanced between groups (eTable 2 in the [Supplement](#)). In comparing the proportion of participants with PRO-CTCAE scores greater than 0 without baseline adjustment to account for pretreatment symptoms, there were 4 AEs with statistically significant differences between groups (anorexia, diarrhea, nausea, and vomiting), whereas use of baseline adjustment yielded 7 AEs with statistically significant differences between groups (anorexia, diarrhea, dyspnea, mucositis, nausea, neuropathy, and vomiting) ([Table](#)). Higher rates were observed in the cabozantinib group for all of these AEs. In the primary reporting of safety data using the CTCAE, no statistically significant differences were found between groups for any symptomatic AEs. Similar results were observed in an analysis restricting AEs to scores of grades of 3 or more.

The [Figure](#) and the eFigure in the [Supplement](#) show the distribution of PRO-CTCAE responses for each week of active therapy through week 24, after which there were fewer than 10 patients still participating per group. The [Figure](#) also displays the maximum postbaseline score without and with baseline adjustment. In AEs with high baseline rates (eg, decreased appetite in [Figure](#), A), adjustment for baseline was substantially associated with summary rates, whereas in AEs with low baseline rates (eg, mouth or throat sores in [Figure](#), B), adjustment for baseline was not substantially associated with summary rates. In receiver operating characteristic curve comparisons, baseline adjustment better differentiated between treatment groups for decreased appetite severity (difference in area under the receiver operating characteristic curve [Δ AUC], 0.12; 95% CI, 0.03-0.12; $P = .008$) and shortness of breath severity (Δ AUC, 0.09; 95% CI, 0.01-0.18; $P = .04$) and interference with daily activities (Δ AUC, 0.09; 95% CI, 0.01-0.17; $P = .03$) (median Δ AUC across the 21 items, 0.04; range, -0.03 to 0.12), leading to a significant overall association (Δ AUC, 0.03; 95% CI, 0.01-0.05; $P = .004$). Overall, higher rates and magnitudes of each symptomatic AE were seen in the cabozantinib group.

Discussion

This study demonstrates that remote electronic collection of PRO-CTCAE data every 3 weeks from patients is feasible with high completion rates even in a heavily pretreated population with end-stage metastatic disease. Moreover, when evaluating tolerability, AEs are better differentiated between study groups with the PRO-CTCAE than the CTCAE, likely owing to the greater

accuracy of patient reporting for symptomatic AEs compared with the current standard of clinician reporting. Overall, patient self-reporting provides a depiction of the patient's experience of treatment that differs from traditional CTCAE data. Because many patients enter clinical trials with baseline symptoms, adjustment for these in analysis of symptomatic AEs is desirable and was successfully applied in this analysis and should be considered for future evaluations of PRO-CTCAE to ensure appropriate attribution to study drugs.

Limitations

This study is limited by its relatively small sample size in a single disease with a relatively young median participant age of 65 years. However, it is not that dissimilar from other cancer clinical trials and offers an example of the implementation of PRO-CTCAE that can be used in the conduct of future studies.

Conclusions

PRO-CTCAE data collection was feasible and improved the accuracy of symptomatic AE detection in a phase 3 cancer trial. This analysis adds to mounting evidence of the feasibility and value of patient-reported AEs in oncology, which should be considered for inclusion in cancer trials that incorporate AE evaluation.

Notes

Supplement.

eTable 1. Compliance Rates for PRO-CTCAE Reports at Successive Weeks of Reporting During Trial Participation, by Study Group

eTable 2. Comparison of PRO-CTCAE Scores Between Study Groups at Baseline (Cabozantinib N = 53, Mitoxantrone-Prednisone N = 54)

eFigure. Distribution of PRO-CTCAE Scores at Successive Time Points During Active Therapy and Maximum Score Postbaseline Without and With Baseline Adjustment, by Study Group

References

1. Basch E, Jia X, Heller G, et al.. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. *J Natl Cancer Inst.* 2009;101(23):-. doi: 10.1093/jnci/djp386 [PMCID: PMC2786917] [PubMed: 19920223] [CrossRef: 10.1093/jnci/djp386]
2. Kluetz PG, Papadopoulos EJ, Johnson LL, et al.. Focusing on core patient-reported outcomes in cancer clinical trials—response. *Clin Cancer Res.* 2016;22(22):5618. doi: 10.1158/1078-0432.CCR-16-2140 [PMCID: PMC5895452] [PubMed: 28151715] [CrossRef: 10.1158/1078-0432.CCR-16-2140]
3. Basch E, Reeve BB, Mitchell SA, et al.. Development of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *J Natl Cancer Inst.* 2014;106(9):dju244. doi: 10.1093/jnci/dju244 [PMCID: PMC4200059] [PubMed: 25265940] [CrossRef: 10.1093/jnci/dju244]

4. Hay JL, Atkinson TM, Reeve BB, et al.; NCI PRO-CTCAE Study Group . Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *Qual Life Res.* 2014;23(1):257-269. doi: 10.1007/s11136-013-0470-1 [PMCID: PMC3896507] [PubMed: 23868457] [CrossRef: 10.1007/s11136-013-0470-1]
5. Dueck AC, Mendoza TR, Mitchell SA, et al.; National Cancer Institute PRO-CTCAE Study Group . Validity and reliability of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *JAMA Oncol.* 2015;1(8):1051-1059. doi: 10.1001/jamaoncol.2015.2639 [PMCID: PMC4857599] [PubMed: 26270597] [CrossRef: 10.1001/jamaoncol.2015.2639]
6. Basch E, Rogak LJ, Dueck AC. Methods for implementing and reporting patient-reported outcome (PRO) measures of symptomatic adverse events in cancer clinical trials. *Clin Ther.* 2016;38(4):821-830. doi: 10.1016/j.clinthera.2016.03.011 [PMCID: PMC4851916] [PubMed: 27045992] [CrossRef: 10.1016/j.clinthera.2016.03.011]
7. Basch EM, Scholz M, de Bono JS, et al.. Cabozantinib versus mitoxantrone-prednisone in symptomatic metastatic castration-resistant prostate cancer: a randomized phase 3 trial with a primary pain endpoint. *Eur Urol.* 2019;75(6):929-937. doi: 10.1016/j.eururo.2018.11.033 [PMCID: PMC6876845] [PubMed: 30528222] [CrossRef: 10.1016/j.eururo.2018.11.033]
8. World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA.* 2013;310(20):2191-2194. doi: 10.1001/jama.2013.281053 [PubMed: 24141714] [CrossRef: 10.1001/jama.2013.281053]
9. Smith M, De Bono J, Sternberg C, et al.. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. *J Clin Oncol.* 2016;34(25):3005-3013. doi: 10.1200/JCO.2015.65.5597 [PubMed: 27400947] [CrossRef: 10.1200/JCO.2015.65.5597]
10. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics.* 1988;44(3):837-845. doi: 10.2307/2531595 [PubMed: 3203132] [CrossRef: 10.2307/2531595]

Figures and Tables

Table.

Rates of PRO-CTCAE Scores Greater Than 0 and 3 or More Between Study Groups During Active Treatment, Without or With Adjustment for Baseline Scores


PRO-CTCAE Item ^a	No.	Cabozantinib	Mitoxantrone- Prednisone	Without Baseline Adjustment			
				Score >0 Cabozantinib, No. (%)	Mitoxantrone- Prednisone, No. (%)	<i>P</i> Value ^b	Score ≥3 Cabozantinib, No. (%)
Constipation							
Severity	53	54		50 (94.3)	47 (87.0)	.32	19 (35.8)
Decreased appetite							
Severity	52	54		50 (96.1)	48 (88.9)	.27	27 (51.9)
Interference	52	54		48 (92.3)	39 (72.2)	.01	23 (44.2)
Diarrhea							
Frequency	52	54		48 (92.3)	34 (63.0)	<.001	23 (44.2)
Fatigue							
Severity	53	54		53 (100)	54 (100)	NA	39 (73.6)
Interference	53	54		53 (100)	54 (100)	NA	40 (75.5)
Insomnia							
Severity	53	54		44 (83.0)	47 (87.0)	.60	10 (18.9)
Interference	53	54		36 (67.9)	41 (75.9)	.40	10 (18.9)
Mouth or throat sores							
Severity	52	54		34 (65.4)	25 (46.3)	.05	6 (11.5)
Nausea							
Frequency	52	54		49 (94.2)	38 (70.4)	.002	25 (48.1)
Severity	52	54		49 (94.2)	36 (66.7)	<.001	21 (40.4)
Numbness or tingling in hands or feet							
Severity	52	54		44 (84.6)	40 (74.1)	.23	16 (30.8)
Interference	52	54		34 (65.4)	26 (48.1)	.08	11 (21.2)
Pain							

Abbreviations: NA, not applicable; PRO-CTCAE, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events.

^aNot all symptoms in the PRO-CTCAE include frequency, severity, and interference; depending on the symptom, anywhere between 1 and 3 attributes are elicited; for details, see <https://healthcaresdelivery.cancer.gov/pro-ctcae/>. Rash is assessed for presence only on a binary 0 or 1 scale.

^bDetermined by use of the Fisher exact test.

Figure.



Distribution of PRO-CTCAE Scores at Successive Time Points During Active Therapy and Maximum Postbaseline Score Without and With Baseline Adjustment, by Study Arm

See eFigure in the [Supplement](#) for all Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) items.

^aMaximum score reported after baseline per patient.

^bMaximum score reported after baseline per patient when including only scores that were worse than the patient's baseline score.